Guardant Reveal

GTR Test IDHelpEach Test is a specific, orderable test from a particular laboratory, and is assigned a unique GTR accession number. The format is GTR00000001.1, with a leading prefix 'GTR' followed by 8 digits, a period, then 1 or more digits representing the version. When a laboratory updates a registered test, a new version number is assigned.: GTR000593766.3
Last updated: 2022-11-30
Annual Review past due read more
Test version history
- 593766.3, last updated: 2022-11-30
- 593766.2, last updated: 2022-11-28
- 593766.1, last updated: 2021-08-13

Clinical testHelpIn the U.S., clinical tests must be performed under CLIA certification. When a lab uses the same methods for a test in both clinical and research settings, the test appears as two separate GTR records. for Colorectal carcinoma
Offered by Guardant Health

Overview

Guardant Reveal

This is a clinical test intended for HelpPurposes or indications for the test. Lab-provided.: Monitoring, Recurrence, Therapeutic management

Click Indication tab for more information.

Licensed physician contacts Guardant Health client services for ordering information.
Order URL HelpLink to the laboratory webpage with information about how to order this test. Please note that clicking on this link will open a new tab in your internet browser.: https://guardantreveal.com/

Specimen source

Peripheral (whole) blood

Plasma

Molecular Genetics
MMethylation analysis Next-Generation (NGS)/Massively parallel sequencing (MPS) Other None/not applicable
ESequence analysis of select exons Next-Generation (NGS)/Massively parallel sequencing (MPS) Other None/not applicable

Summary of what is tested

Click Methodology tab for more information.

Guidance for management

Citations

https://www.guardanthealth.com/

A total of 252 prospective serial plasma specimens from 103 patients with colorectal cancer undergoing curative-intent surgery were analyzed and correlated with recurrence. Plasma-only MRD detection demonstrated favorable sensitivity and specificity for recurrence, comparable with tumor-informed approaches. Integrating analysis of epigenomic and genomic alterations enhanced sensitivity. These findings support the potential clinical utility of plasma-only ctDNA MRD detection.

Citations

Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer. - PubMed ID: 33926918

An approved physician with a Guardant Health account uses the Guardant sample collection kit to obtain a whole blood sample from the patient. Following Guardant shipping instructions, the sample is sent directly to the laboratory at Guardant Health. Turn around time for testing is 14 days. 000 Licensed physician contacts Guardant Health client services for ordering information.

Liquid biopsy testing for somatic cancer gene variants
Liquid biopsy testing for MRD

Reviews

Clinical resources

Practice guidelines

DailyMed Drug Label, 2021
DailyMed Drug Label, Capecitabine, 2021

Consumer resources

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.

Guardant Reveal

Overview

Test name

Purpose of the test

Condition

How to order

Specimen source

Methodology

Summary of what is tested

Clinical utility

Guidance for management

Clinical validity

Testing strategy

Test services

Reviews

Clinical resources

Practice guidelines

Consumer resources